Retention and migration of a specially designed alprostadil transdermal cream was assessed after single-dose administration to the glans meatus of the penis. Seven men were enrolled in this twoway crossover study. Three subjects self-administered the radio-labeled alprostadil transdermal cream (B100 mg of cream containing 300 lg alprostadil) by inserting the tip of the dispenser into the meatus. In three others, the dose was administered by dispensing the cream dropwise into the metal opening without touching the penis (the preferred and directed method). Retention and migration of the cream mass was measured in the penis with a gamma scintillation camera. The alprostadil transdermal cream was retained in the fossa navicularis at or near 99% in five of six subjects regardless of the method of dosing, thus indicating that the cream formulation performed as designed. A mild, transient burning sensation in the penis was the most common adverse event.
Introduction
The worldwide prevalence of erectile dysfunction (ED) is high, and it rises with increasing age. [1] [2] [3] Diagnoses of ED have increased following the advent of safe, effective, and convenient treatment, 4 and this trend will likely continue as the US and European populations age. The prevalence of ED is particularly high among patients with cardiovascular risk factors, including hypertension, diabetes, and coronary artery disease (CAD). 1, [5] [6] [7] [8] The treatment of ED is based on psychosexual counseling or on pharmacotherapy involving phosphodiesterase type-5 (PDE-5) inhibitors. A considerable number of patients, however, do not respond to or accept these therapies, and some patients may be undergoing pharmacotherapy (such as nitrate therapy) or have conditions (such as retinitis pigmentosa) that are considered absolute contraindications to PDE-5 inhibitor therapy. Others may risk adverse drug interactions with alpha-blockers or multidrug antihypertensive therapy. 4 Alprostadil is a current alternative, which can be administered as an intraurethral suppository or an intracavernosal injection, although these options necessitate patient training and are inconvenient, cumbersome, and invasive. Thus, a need exists for a patient-friendly treatment option that can be prescribed by primary care doctors.
Alprostadil transdermal cream (Alprox-TD s , NexMed, Inc., Robbinsville, NJ, USA) has been developed as a first-choice treatment alternative for patients with ED. Efficacy via intra-meatal delivery of alprostadil has been achieved by formulating the drug in a new, proprietary skin permeation-enhancing delivery technology (NexACT s , NexMed, Inc., Robbinsville, NJ, USA). The cream is designed for retention in the meatus and fossa navicularis of the penis until absorption of the active ingredient, alprostadil, is achieved. The cream is simply dropped from a dispenser onto the glans meatus, where it is absorbed directly into the penile tissue.
The efficacy and safety of alprostadil transdermal cream have been shown in two randomized, multicenter, parallel-group, double-blind, placebo-controlled phase II clinical trials. 9, 10 Compared with patients given placebo, those given alprostadil transdermal cream showed significant improvement in several critical measures of erectile function. The treatment was also safe and well tolerated, with mild adverse effects limited to the area of application. Two phase III trials have recently been completed. In this study, we used gamma scintigraphy to measure the retention and migration of radiolabeled alprostadil transdermal cream in healthy volunteers.
Methods
This two-way crossover study measured the retention and migration of the transdermal cream formulation of alprostadil in healthy volunteers by using both nonabsorbable and absorbable radiolabeled markers and a preferred and directed method as well as an incorrect dispensing method. The study was approved by the Schulman Associates Institutional Review Board, Inc., and was conducted in accordance with the ethical principles derived from the Declaration of Helsinki. Written, informed consent was obtained from each subject prior to the start of the study.
Volunteers eligible for the study included those who were in good physical and mental health, as determined by their medical history and results of a physical examination, which included routine clinical laboratory tests, normal lipid chemistry, and urinalysis. Subjects could be included if they were 22-36 y of age and had a small to medium body frame and a body mass index within 10% above or below the acceptable range. Sexually active subjects had agreed to use adequate birth control during the study and for 2 weeks afterward to prevent their partners' pregnancy.
Subjects were excluded if they had participated in a similar study involving the use of radioisotopes during the previous 6 months or had been exposed to any radiation, including X-rays (but excluding those used in extremity or dental radiography), within the previous 3 months. Subjects were also excluded if they had participated in an investigational drug study within 1 month of the physical examination or planned to participate in any investigational drug study while in this drug trial. Subjects were also ineligible if they had a verifiable history of allergy or hypersensitivity to any transdermal skin formulation, or of seizures or a condition affecting the heart, kidneys, liver, glands, or intestinal tract. Subjects with a history, or current evidence, of abuse of any drug substance, licit or illicit, including alcohol, were excluded. Finally, subjects who routinely used gamma-emitting radioactive isotopes, as would be necessary in training or employment related to medicine or dentistry, were ineligible to participate in this study.
Within 7 days of the study, subjects provided a medical history and underwent a brief physical examination, including routine clinical laboratory evaluations of the blood and urine. Six men aged 22-36 y were to be included in the study. A seventh qualified subject was retained as an alternate for the duration of the study in case one of the others dropped out or was excluded.
All subjects were studied during a single 2-day period. On day 1, each subject self-administered alprostadil transdermal cream (B100 mg of cream containing 300 mg alprostadil) that was mixed with a radiolabeled nonabsorbable 99m Tc-sulfur colloid. On day 2, each subject self-administered alprostadil transdermal cream (B100 mg of cream containing 300 mg alprostadil) mixed with a radiolabeled 99m Tchexamethylpropylene amine oxime (HMPAO), an absorbable radiolabeled marker. These markers are gamma-ray-emitting radionuclides that are routinely used for diagnostic imaging. The 99m Tc-sulfur colloid formulation was used to evaluate the potential migration of the cream mass, while the 99m Tc-HMPAO formulation was used to evaluate vascular absorption.
Three subjects inserted the tip of the dispenser directly into the meatus-that is, the distal opening of the fossa navicularis-and then dispensed the study medication, whereas the remaining three subjects dispensed the study medication to the meatus without inserting the tip of the dispenser (the method specified for patients in ongoing phase III clinical trials). After dispensing the dose, each subject was placed in a supine position beneath a scintillation camera, where the subject's penis was taped to the lower abdomen to avoid lateral movement during data acquisition. Anterior and lateral views of each subject's penis were acquired and the resultant data summed for analysis. The retention of each study medication was monitored using a gamma scintillation camera at 1-min intervals for 30 min. The data acquisition rate was 1 min per computer frame.
Control subjects were not enrolled, and neither the subjects nor the investigators were blinded to the formulations administered. Although health risks associated with the study drugs were negligible, safety monitoring continued throughout the 30-min data acquisition period on each study day.
Scintigraphy images and data analysis included a computer display of each subject's experimental study, followed by a selection of computer regions of interest (ROIs). The anatomical ROIs were the distal portion and entire shaft of the penis. Since 30 individual computer frames of data were collected, all 30 computer frames were summed to reveal one composite image. This procedure was performed to reduce any uncertainty regarding the migration of a formulation along the shaft of the penis and to avoid erroneous analysis of low-level radioactivity that may be evident in any individual frame. The visual presence of the retained radiolabeled formulation aided in the drawing of the regions to ensure accuracy for location. For each ROI selected, a computer command was used to generate a radiation count within a selected pixel region. Descriptive statistics and standard deviations (s.d.) were used to determine the retention and migration of each alprostadil transdermal cream dose. The mean retention after the two doses was compared using an analysis of variance (ANOVA). The level of significance was prospectively defined at Po0.05. Safety was assessed by recording any adverse events noted by the investigator, the study staff, or the subjects.
Results
One enrolled subject withdrew consent prior to the start of the study and was replaced by the alternate. Of the six subjects who completed the study, one (aged 42) was outside the specified age range. The study group's mean (s. Tc-HMPAO formulation it was 106.6 (6.5) mg (day 2).
In one subject given the alprostadil transdermal cream radiolabeled with the nonabsorbing 99m Tcsulfur colloid, 93.25% of the dose was retained (Table 1a ). The remaining 6.75% migrated 3 cm proximally in the urethra from the point of application, with a trace migrating 7 cm (Figure 1a ). In the other five subjects, dose retention was at or near 99% and the proportion of the dose that migrated was approximately 1% (Figure 1b) . In these five subjects, the migration was limited generally to 2 cm or less, although in one patient a trace migration of 4 cm was observed.
On day 2, the same subject who previously demonstrated 93.25% dose retention with the 99m Tc-sulfur colloid experienced 90.36% retention of the study medication radiolabeled with 99m Tc-HMPAO (Table 1b) . The remaining 9.64% migrated about 1.5 cm along the penile shaft, with a trace migrating 7 cm (Figure 2a) . Dose retention in all other subjects was at or near 99% and the proportion Among all six subjects, the mean (s.d.) proportion of radiolabeled alprostadil transdermal cream retained in the glans was 98.11% (2.39%) on day 1 (nonabsorbable sulfur colloid formulation) and 97.63% (3.58%) on day 2 (absorbable HMPAO formulation). When the means were compared using an ANOVA, no statistically significant difference in retention of the two study medication radiolabels was observed (P40.05).
Three subjects inserted the tip of the dispenser into the meatus and one of these subjects reported and demonstrated an erection on day 1, which was observed on the scintigraphic image. No other subjects reported an erection after self-administering either formulation, nor were any erections observed on the scintigraphic images.
The only adverse event reported (by four of six subjects) was mild penile pain that lasted 10-30 min.
Comment
Until late in the last century, treating ED was inconvenient, awkward, and sometimes painful; thus, the advent of safe and effective oral treatment with the PDE-5 inhibitors has helped to rapidly raise the awareness of ED and the numbers of patients who now seek treatment. However, PDE-5 inhibitor therapy is absolutely contraindicated in patients taking nitrates and in patients with retinitis pigmentosa, and a considerable number of patients fail oral therapy, cannot tolerate it, or choose not to take it. 4 For these patients, the least invasive alternative represents the best treatment option.
ED is associated with aging and several important cardiovascular risk factors including diabetes, lipid abnormalities, smoking, hypertension, obesity, and a lack of physical activity. 11 As we understand more about the relationship between ED and CAD, ED may emerge as a sentinel for ischemic heart disease, 12, 13 especially among patients with type II diabetes, 14 thus helping physicians to diagnose and treat CAD in men who otherwise might not have been identified.
The efficacy of alprostadil is well appreciated for the treatment of patients with ED when given as intracavernosal injections or intraurethral suppositories, but these routes of administration are very inconvenient to use. Considerable effort, therefore, has gone into formulating alprostadil into a topically applied noninvasive treatment, that is, one that does not require the insertion of a suppository into the urethra or hypodermic injection into the cavernosa. Topically applied alprostadil has been shown to increase intracavernosal pressure in a dose-dependent fashion in an animal model, 15 and to increase cavernosal artery peak systolic velocity in humans. 16 Moreover, the efficacy of topically applied alprostadil in humans has been established in several clinical trials. 9, 10, 17 The formulation evaluated in this study is designed to be used easily and conveniently by just dripping the cream onto the glans meatus where it is largely retained, allowing local absorption of the active ingredient.
In the present trial, with the use of gamma scintigraphy, we demonstrated that both the absorb- Retention and migration of alprostadil cream J Yeager and RM Beihn able and nonabsorbable radiolabeled formulations of alprostadil transdermal cream are retained in the fossa navicularis in similar proportions and that the degree of dose migration or absorption associated with the two formulations also did not differ significantly. Although the sample is small, the methods are appropriate and objective and the data quantifiable. Thus, these results indicate that alprostadil transdermal cream performs as designed and remains almost entirely at the site of application; that is, the cream does not migrate proximally through the urethra, even when administered by inserting the dispenser directly in the glans meatus. Exposure to the alprostadil transdermal cream was well tolerated.
No unexpected adverse events were reported. A single erection was observed among the six subjects in this study. This result was not unexpected because topically applied alprostadil at doses of 400 mg produced erections in only 20% of the patients without sexual stimulation in a placebo controlled trial. 18 In another study, 67% of the patients obtained an erection with the aid of visual and tactile sexual stimulation after the topical application of 500 mg alprostadil, but the effect could not be maintained without sexual stimulation. 16 By way of comparison, most of the patients in the transurethral alprostadil (MUSE system) clinical trials received 500 or 1000 mg of alprostadil, and in these trials patients were instructed to engage in sexual stimulation before attempting intercourse. 19 Alprostadil transdermal cream may become a firstline alternative to PDE-5 inhibitors when such drugs are contraindicated or prove ineffective or are otherwise not accepted or tolerated. Some patients may also prefer a transdermal cream as a first-line therapy especially if clinical trials verify that the onset of action is faster than that of oral treatment. The transdermal formulation of alprostadil is easy to use and noninvasive, and it has little or no potential for producing systemic adverse effects or harmful drug interactions. In two phase II trials that included patients with cardiovascular disease and diabetes, alprostadil transdermal cream was shown to significantly improve erectile function domain scores on the International Index of Erectile Function and scores related to other important measures of efficacy, such as the vaginal penetration success rate and patient self-rating of erection. In these trials, adverse events, which were localized to the application site, were transient and mild to moderate in intensity. 9, 10 The safety and efficacy of alprostadil transdermal cream and its role in the treatment of ED will be better defined by the findings of two recently completed phase III clinical trials.
